563 related articles for article (PubMed ID: 1759092)
1. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem.
Kryger MH; Steljes D; Pouliot Z; Neufeld H; Odynski T
Sleep; 1991 Oct; 14(5):399-407. PubMed ID: 1759092
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of EEG cyclic alternating pattern during sleep in insomniacs and controls under placebo and acute treatment with zolpidem.
Terzano MG; Parrino L
Sleep; 1992 Feb; 15(1):64-70. PubMed ID: 1557595
[TBL] [Abstract][Full Text] [Related]
3. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation.
Herrmann WM; Kubicki ST; Boden S; Eich FX; Attali P; Coquelin JP
J Int Med Res; 1993; 21(6):306-22. PubMed ID: 8143886
[TBL] [Abstract][Full Text] [Related]
4. Nonorganic insomnia in generalized anxiety disorder. 2. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods.
Saletu B; Saletu-Zyhlarz G; Anderer P; Brandstätter N; Frey R; Gruber G; Klösch G; Mandl M; Grünberger J; Linzmayer L
Neuropsychobiology; 1997; 36(3):130-52. PubMed ID: 9313245
[TBL] [Abstract][Full Text] [Related]
5. Effect of zolpidem on sleep architecture and its next-morning residual effect in insomniac patients: a randomized crossover comparative study with brotizolam.
Uchimura N; Nakajima T; Hayash K; Nose I; Hashizume Y; Ohyama T; Habukawa M; Kotorii N; Kuwahara H; Maeda H
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):22-9. PubMed ID: 16048734
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
7. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia.
Erman MK; Zammit G; Rubens R; Schaefer K; Wessel T; Amato D; Caron J; Walsh JK
J Clin Sleep Med; 2008 Jun; 4(3):229-34. PubMed ID: 18595435
[TBL] [Abstract][Full Text] [Related]
8. Placebo-controlled sleep laboratory studies on the acute effects of zolpidem on objective and subjective sleep and awakening quality in nonorganic insomnia related to neurotic and stress-related disorder.
Saletu-Zyhlarz G; Anderer P; Brandstätter N; Dantendorfer K; Gruber G; Mandl M; Ritter K; Zoghlami A; Saletu B
Neuropsychobiology; 2000; 41(3):139-48. PubMed ID: 10754428
[TBL] [Abstract][Full Text] [Related]
9. CAP variables and arousals as sleep electroencephalogram markers for primary insomnia.
Terzano MG; Parrino L; Spaggiari MC; Palomba V; Rossi M; Smerieri A
Clin Neurophysiol; 2003 Sep; 114(9):1715-23. PubMed ID: 12948801
[TBL] [Abstract][Full Text] [Related]
10. Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans.
Morgan PT; Kehne JH; Sprenger KJ; Malison RT
J Sleep Res; 2010 Mar; 19(1 Pt 2):157-64. PubMed ID: 19682231
[TBL] [Abstract][Full Text] [Related]
11. Effects of zolpidem on cyclic alternating pattern, an objective marker of sleep instability, in Japanese patients with psychophysiological insomnia: a randomized crossover comparative study with placebo.
Ozone M; Yagi T; Itoh H; Tamura Y; Inoue Y; Uchimura N; Sasaki M; Shimizu T; Terzano MG; Parrino L
Pharmacopsychiatry; 2008 May; 41(3):106-14. PubMed ID: 18484552
[TBL] [Abstract][Full Text] [Related]
12. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.
Elie R; Rüther E; Farr I; Emilien G; Salinas E
J Clin Psychiatry; 1999 Aug; 60(8):536-44. PubMed ID: 10485636
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
[TBL] [Abstract][Full Text] [Related]
14. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.
Roth T; Hull SG; Lankford DA; Rosenberg R; Scharf MB;
Sleep; 2008 Sep; 31(9):1277-84. PubMed ID: 18788653
[TBL] [Abstract][Full Text] [Related]
15. Conventional and power spectrum analysis of the effects of zolpidem on sleep EEG in patients with chronic primary insomnia.
Monti JM; Alvariño F; Monti D
Sleep; 2000 Dec; 23(8):1075-84. PubMed ID: 11145322
[TBL] [Abstract][Full Text] [Related]
16. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal.
Vandrey R; Smith MT; McCann UD; Budney AJ; Curran EM
Drug Alcohol Depend; 2011 Aug; 117(1):38-44. PubMed ID: 21296508
[TBL] [Abstract][Full Text] [Related]
17. Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial.
Dockhorn RJ; Dockhorn DW
Clin Neuropharmacol; 1996 Aug; 19(4):333-40. PubMed ID: 8828996
[TBL] [Abstract][Full Text] [Related]
18. Effects of flurazepam and zolpidem on the perception of sleep in insomniacs.
Mendelson WB
Sleep; 1995 Feb; 18(2):92-6. PubMed ID: 7792498
[TBL] [Abstract][Full Text] [Related]
19. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo.
Roth T; Roehrs T; Vogel G
Sleep; 1995 May; 18(4):246-51. PubMed ID: 7618022
[TBL] [Abstract][Full Text] [Related]
20. Dose response effects of zolpidem in normal geriatric subjects.
Scharf MB; Mayleben DW; Kaffeman M; Krall R; Ochs R
J Clin Psychiatry; 1991 Feb; 52(2):77-83. PubMed ID: 1993640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
